Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 20/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998936 | 0.86 | CHRM1 (0.51) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL15618700 | 0.85 | CHRM1 (0.53) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL15618889 | 0.85 | MAPT (0.52) | CHRM1CHRM2CHRM5 | |
| SCHEMBL2191074 | 0.83 | CHRM1 (0.61) | CHRM1CHRM2CHRM5CHRM3CHRM4 | |
| SCHEMBL2996155 | 0.82 | CHRM1 (0.50) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL22032115 | 0.79 | CHRM1 (0.53) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL20901307 | 0.79 | CHRM1 (0.48) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL20901306 | 0.79 | CHRM1 (0.48) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL13209510 | 0.79 | CHRM1 (0.46) | CHRM1CHRM2CHRM5CHRM4 | |
| SCHEMBL13209533 | 0.78 | CHRM1 (0.45) | CHRM1CHRM2CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786308-B2 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080090826-A9 | Muscarinic modulators | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2008-04-17 | — | — | US | disclosed |
| EP-1863490-A2 | MUSCARINIC MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| US-20070054911-A1 | Muscarinic modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2007-03-08 | — | — | US | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054911-A1 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | CHRM1 5/4885CHRM2 4/4885CHRM5 2/4885 |
| US-20080090826-A9 | Muscarinic modulators | CHRM3, CHRM5, CHRM4 | CHRM1 5/4885CHRM2 4/4885CHRM5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.